To the Editor Dr Basch and colleagues found a survival benefit of 5 months with symptom monitoring via electronic patient-reported symptom monitoring compared with usual care in patients with metastatic cancer.1 The primary outcome of their study was change in health-related quality of life after 6 months, which was significantly greater in the intervention group than in the control group.2 In addition, the 1-year overall survival was 6% higher in the intervention group (75% in the intervention group vs 69% in the usual care group).2 Before randomization, patients were stratified into a computer-experienced group or a computer-inexperienced group, consisting of patients who had less than weekly access to email or a computer. Subgroup analyses showed a significant improvement in 1-year survival in the computer-inexperienced group, whereas no survival benefit was observed in the computer-experienced group.
Douma JAJ, Buffart LM, Verheul HMW. Patient-Reported Symptom Monitoring During Chemotherapy. JAMA. 2017;318(19):1935. doi:10.1001/jama.2017.14899
Customize your JAMA Network experience by selecting one or more topics from the list below.